Meet us at LSX Nordic Congress

July 26 | 2018

2cureX participates in Life Science Executives, Leadership and Investment Congress in Stockholm, 29th to 30th August 2018, where CEO Ole Thastrup talks about 2cureX and our product IndiTreat®, which helps clinicians choose the most appropriate treatment for cancer patients.

Certified Adviser

Sedermera Fondkommission is the Certified Adviser of 2cureX.

For more information about 2cureX:

Ole Thastrup, CEO;

E-mail: ot@2cureX.com

Phone: +45 22 11 53 99;

URL: www.2curex.com

About 2cureX

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.

IndiTreat® is currently being clinically validated in colorectal and ovarian cancer.

The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).